Literature DB >> 14655007

[Therapy of postmenopausal osteoporosis].

E Keck1.   

Abstract

The therapy of postmenopausal osteoporosis is based on a few comprehensible assumptions. High bone resorption should be reduced by treatment with bisphosphonates, raloxifene or seldom with calcitonins. After reduction of high bone turnover and in low bone turnover situations, an osteoinductive combination therapy should be started, inducing collagen type I with parathyroid hormone or fluorides. This collagen can then be mineralized by calcium, vitamin D, and vitamin D metabolites. In addition, bone resorption should be reduced during menopause with estrogens and gestagens, in the case of a receptor-positive breast cancer with tamoxifen, and after menopause with raloxifene or a bisphosphonate. In elderly patients a depletion of vitamin D often induces an osteoporomalacia instead of an osteoporosis. In this situation, mineralization of the osteoid by calcium and vitamin D is sufficient for therapy. A daily osteoporosis gymnastic program is required and physical activity should be enhanced to increase muscle mass because bone adapts to the individual situation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14655007     DOI: 10.1007/s00132-003-0561-8

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  4 in total

1.  Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures.

Authors:  C Y Pak; K Sakhaee; J E Zerwekh; C Parcel; R Peterson; K Johnson
Journal:  J Clin Endocrinol Metab       Date:  1989-01       Impact factor: 5.958

2.  Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.

Authors:  R Lindsay; J Nieves; C Formica; E Henneman; L Woelfert; V Shen; D Dempster; F Cosman
Journal:  Lancet       Date:  1997-08-23       Impact factor: 79.321

3.  Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study.

Authors:  P Alexandersen; B J Riis; C Christiansen
Journal:  J Clin Endocrinol Metab       Date:  1999-09       Impact factor: 5.958

4.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Authors:  R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak
Journal:  N Engl J Med       Date:  2001-05-10       Impact factor: 91.245

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.